European regulators will write simple versions of drug safety bulletins. In technical parlance, the EMEA says, summaries of European public assessment reports (EPARs) will be intended for ordinary patients. Each summary will have explanation of how the drug works, what ailments it should be used for, how it was studied, its benefits and risks, and the reason it was approved for sale by the EMEA. For now, the Europeans say, they will only issue summaries for new drugs. But over time, the documents will be issued for all centrally approved medicines for animals and humans.